Company intelligence / Profile preview

BlackSwan Vascular

Hayward, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 3

Overview

The pivotal LAVA Study enrolled 113 patients at 20 centers and demonstrated that the Lava LES exceeded safety and efficacy performance goals. Safety was measured by freedom from major adverse events at day 30; effectiveness was defined as no bleeding from the target lesion after embolization with no need for emergency surgery or reintervention at day 30. FDA premarket approval was granted based on these results.

Therapeutic areas: OncologyCardiovascular
Modalities: DeviceLiquid embolic agent
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

Lava

Phase 3

Indications: Peripheral vascular applications, Arterial hemorrhage

1 more asset in the full pipeline.

Request access →

Partnerships

Sirtex MedicalGrand Pharmaceutical

Beyond the preview

Go deeper on BlackSwan Vascular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BlackSwan Vascular.

Explore the full profile